X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (505) 505
female (328) 328
male (255) 255
dalteparin (244) 244
anticoagulants - adverse effects (212) 212
middle aged (209) 209
anticoagulants - therapeutic use (207) 207
index medicus (203) 203
aged (199) 199
adult (186) 186
dalteparin - adverse effects (183) 183
dalteparin - therapeutic use (179) 179
molecular-weight heparin (155) 155
hematology (147) 147
anticoagulants - administration & dosage (145) 145
dalteparin - administration & dosage (145) 145
enoxaparin (130) 130
treatment outcome (127) 127
peripheral vascular disease (126) 126
venous thromboembolism (122) 122
prevention (121) 121
thromboembolism (119) 119
heparin (116) 116
thrombosis (107) 107
aged, 80 and over (104) 104
risk factors (100) 100
deep-vein thrombosis (97) 97
unfractionated heparin (97) 97
anticoagulants (95) 95
prophylaxis (92) 92
prospective studies (90) 90
heparin, low-molecular-weight - therapeutic use (89) 89
hemorrhage - chemically induced (85) 85
heparin, low-molecular-weight - adverse effects (83) 83
venous thrombosis - prevention & control (79) 79
surgery (70) 70
time factors (70) 70
heparin, low-molecular-weight - administration & dosage (69) 69
thromboprophylaxis (69) 69
pregnancy (68) 68
venous thromboembolism - prevention & control (67) 67
thromboembolism - prevention & control (64) 64
low-molecular-weight heparin (62) 62
medicine, general & internal (61) 61
venous thrombosis (59) 59
drug therapy (58) 58
heparin - adverse effects (57) 57
injections, subcutaneous (57) 57
drug administration schedule (56) 56
pulmonary-embolism (56) 56
pharmacology & pharmacy (54) 54
fibrinolytic agents - adverse effects (53) 53
low molecular weight heparin (52) 52
enoxaparin - therapeutic use (51) 51
heparin - therapeutic use (51) 51
venous thrombosis - drug therapy (50) 50
fibrinolytic agents - administration & dosage (49) 49
cardiac & cardiovascular systems (48) 48
fibrinolytic agents - therapeutic use (48) 48
double-blind method (46) 46
postoperative complications - prevention & control (46) 46
retrospective studies (46) 46
risk (46) 46
therapy (46) 46
enoxaparin - adverse effects (45) 45
dose-response relationship, drug (43) 43
medicine & public health (43) 43
incidence (42) 42
anticoagulation (41) 41
cancer (41) 41
double-blind (41) 41
randomized controlled trials as topic (41) 41
venous thromboembolism - etiology (41) 41
warfarin (39) 39
pulmonary embolism - prevention & control (38) 38
thrombosis - prevention & control (37) 37
pulmonary embolism (36) 36
recurrence (36) 36
enoxaparin - administration & dosage (35) 35
risk assessment (35) 35
venous thrombosis - etiology (35) 35
adolescent (34) 34
follow-up studies (34) 34
analysis (33) 33
neoplasms - complications (33) 33
pharmacokinetics (33) 33
care and treatment (32) 32
metaanalysis (31) 31
research (31) 31
arthroplasty, replacement, hip - adverse effects (30) 30
deep vein thrombosis (30) 30
heparin - administration & dosage (30) 30
thrombocytopenia - chemically induced (30) 30
abridged index medicus (29) 29
dalteparin - pharmacology (29) 29
oncology (29) 29
safety (29) 29
standard heparin (29) 29
thrombosis - drug therapy (29) 29
warfarin - therapeutic use (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (519) 519
German (12) 12
French (7) 7
Spanish (6) 6
Norwegian (4) 4
Russian (2) 2
Swedish (2) 2
Czech (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 06/2013, Volume 158, Issue 11, pp. 800 - 806
Journal Article
Clinical Orthopaedics and Related Research, ISSN 0009-921X, 02/2018, Volume 476, Issue 2, pp. 381 - 387
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2011, Volume 364, Issue 14, pp. 1305 - 1314
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 09/2018, Volume 16, Issue 9, pp. 1891 - 1894
PROPHYLAXIS | THERAPY | THROMBOSIS | SAFETY | DISEASE | PREVENTION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | GUIDELINE | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants
Journal Article
Circulation, ISSN 0009-7322, 10/1999, Volume 100, Issue 15, pp. 1602 - 1608
Journal Article
Circulation, ISSN 0009-7322, 08/2004, Volume 110, Issue 7, pp. 874 - 879
Journal Article
Journal Article